Exosomal transfer of miR-146a-5p further reduces trastuzumab sensitivity in sensitive cells.217 Therefore, targeting miRNAs or their exosomal transfer could be a promising strategy to overcome resistance and improve the efficacy of immune-based therapies in HER2-positive breast cancer. Here, ERBB2 is linked to breast carcinoma.